ClinicalTrials.gg
CompletedNCT01951157Updated Sep 24, 2019Results posted

A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) Patients

A Phase 2 interventional study of Docetaxel and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC), sponsored by PharmaMar. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-09-24.

Sponsored by PharmaMar · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States — 519 open to participants now, 894 under way, 142 of them phase 3. Carcinoma, Non-Small-Cell Lung · United States.

Enrollment
1,300th of 2,995
69 · median 56
Started
2013
with 100 others
Phase 2
1,078 of 3,368
119 open now
Registered
1,350th of 3,368
by date

Among the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, this one is the 1,300th largest by enrollment of the 2,995 interventional ones that give a count, is one of 101 that started in 2013, is one of 1,078 in phase 2, and was the 1,350th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

519 of the 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States are open now. Recruiting first, the newest first:

514 more — sign in →

All 519 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,368 studies in Carcinoma, Non-Small-Cell Lung with a site in United States, or all of them as a file.
02

Study summary

A clinical study of lurbinectedin(PM01183) alone or in combination with gemcitabine in comparison to docetaxel for the treatment of unresectable non-small cell lung cancer (NSCLC)patients

Read the detailed description

A randomized-controlled, three-arm, phase II study of lurbinectedin (PM01183) alone or in combination with gemcitabine and a control arm with docetaxel as second-line treatment in unresectable non-small cell lung cancer (NSCLC)patients to evaluate the antitumor activity as progression-free survival at four months (PFS4) of PM01183 alone or in combination with gemcitabine as using single agent docetaxel as a reference in the control arm as current standard of care and to analyze overall survival (OS), overall survival rate at 1-year (OS12), duration of response (DR), antitumor activity, as response rate (RR), safety and efficacy profiles of PM01183 alone and in combination with gemcitabine, to be preliminary compared with docetaxel, patients' quality of life (QoL), pharmacokinetics (PK) of PM01183, pharmacokinetic/pharmacodynamic (PK/PD)correlation and pharmacogenomics (PGx)to explore potential correlations between clinical outcomes and molecular parameters found in tumor and blood samples

03

Conditions studied

  • Non-Small Cell Lung Cancer (NSCLC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed unresectable NSCLC
  • Patients must have failed one prior line of CT-based therapy for unresectable disease
  • Age between 18 and 75 years
  • (ECOG)performance status (PS) ≤ 1
  • Adequate hematological, renal, metabolic and hepatic function
  • At least three weeks since the last prior therapy, at least four weeks since completion of any prior radiotherapy
  • Negative pregnancy test for pre-menopausal women

Exclusion criteria

Exclusion Criteria:

  • Concomitant diseases/conditions as unstable angina, myocardial infarction, symptomatic congestive heart failure or asymptomatic with (LVEF) ≤ 50%, dyspnea, infection by (HIV), active virus (HBV) or virus (HCV) infection, active uncontrolled infection, pleural or pericardial effusions, myopathy, limitation of the patient's ability to comply with the treatment or to follow-up the protocol, any other major illness
  • Histological features of neuroendocrine or bronchioalveolar differentiation.
  • Unknown epidermal growth factor receptor (EGFR)mutation status or previously known EGFR mutated status in patients with adenocarcinoma.
  • Prior or concurrent invasive malignant disease, unless in complete remission for more than three years.
  • Significant cancer-related weight loss (≥10%)within four weeks prior to treatment start
  • Prior treatment with docetaxel-containing therapy
  • Symptomatic, -requiring or progressive central nervous system (CNS) involvement
  • Paraneoplastic syndromes
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Active comparator
    A - docetaxel

    75 mg/m2 docetaxel day 1, 1-hour intravenous, every three weeks

    Drug: Docetaxel

  • Experimental
    B - lurbinectedin (PM01183)

    3.2 mg/m2 PM01183, day 1, 1-hour intravenous, every three weeks

    Drug: Lurbinectedin (PM01183)

  • Experimental
    C - gemcitabine + lurbinectedin (PM01183)

    800 mg/m2 gemcitabine / 1.6 mg/m2 PM01183 both on day 1 and day 8, 30-minutes gemcitabine/1-hour PM01183 intravenous, every three weeks

    Drug: Gemcitabine · Drug: Lurbinectedin (PM01183)

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-free Survival Rate at Four Months (PFS4)

    The rate estimate of the percentage of patients who are alive and progression-free at 16 weeks (\~4 months) after randomization. Progession disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Time frame: At month four after patient inclusion

Secondary outcomes

  1. Progression-free Survival

    PFS, progression-free survival Progression-free survival (PFS), defined as the time from the date of randomization to the date of PD, death (of any cause), or last tumor evaluation. Progession disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Time frame: Time from the date of randomization to the date of PD, death (of any cause), or last tumor evaluation, whichever came first, assessed up to 3 years

  2. Progression-free Survival Rate at Six Months (PFS6)

    The rate estimate of the percentage of patients who are alive and progression-free at 24 weeks (\~6 months) after randomization. Progession disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

    Time frame: At month six after patient inclusion

  3. Overall Response Rate

    Overall response rate (ORR) was defined as the percentage of patients with a response, either CR or PR, according to RECIST v.1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Time from the date of randomization until 30±7 days after the last treatment infusion, assessed up to 3 years

  4. Objective Response Per RECIST v.1.1

    RECIST, Response Evaluation Criteria In Solid Tumors Complete Response (CR) Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10mm Partial Response (PR) At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters Progressive Disease (PD) At least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. Appearance of new lesions was considered PD Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum diameters while on study Treatment failure (TF) Symptomatic deterioration/death due to progression or treatment discontinuation due to treatment-related toxicity occurred before any appropriate tumor assessments had been performed

    Time frame: Time from the date of randomization until 30±7 days after the last treatment infusion, assessed up to 3 years

  5. Duration of Response

    Duration of response (DR) was defined as the time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: The time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented, up to 3 years

  6. Overall Survival (OS)

    Overall survival (OS) will be defined as time from the date of first infusion to the date of death or last contact

    Time frame: From the date of first infusion to the date of death or last contact, up to 12 months after last patient inclusion

  7. Information on Quality of Life (QoL)

    The mean QoL scores self-reported by patients using the Lung Cancer Symptom Scale (LCSS) at baseline and after the start of the therapy in visits 3 or 6 (+/- 1 visit) and visit 9 for those patients in maintenance therapy. Higher LCSS scores indicate more severe problems and the scale range is (0-100) Total score was calculated as the mean of the total scores of all nine patient ítems (Appetite, Fatigue, Cough, Dyspnea, Hemoptysis, Pain, Lung cancer symptoms, Normal activities, Global QoL)

    Time frame: Baseline, Cycle 3 (~9 weeks), Cycle 6 (~18 weeks) and Cycle 9 (~27 weeks)

07

Results

Posted Sep 24, 2019

Participant flow

69 patients were enrolled between 11/09/2013 and 2/10/2015 at 13 centers. 68 patients were treated: 22 in Arm A, 21 in Arm B, and 25 in Arm C. The first dose of the first cycle was administered on 17/09/2013 and the last dose of the last cycle was administered on 3/11/2016. The last patient, last follow-up was on 24/11/2016

Participant flow — Overall Study
MilestoneA - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)
Started222225
Completed000
Not completed222225
Withdrew: Progressive disease121310
Withdrew: Treatment-unrelated ae103
Withdrew: Study termination001
Withdrew: Physician decision532
Withdrew: Non-treatmentrelated death222
Withdrew: No treated010
Withdrew: Treatment-related ae204
Withdrew: Consent withdrawn by subject013
Withdrew: Treatment-related death020

Outcome measures

PrimaryProgression-free Survival Rate at Four Months (PFS4)

The rate estimate of the percentage of patients who are alive and progression-free at 16 weeks (\~4 months) after randomization. Progession disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Time frame:
At month four after patient inclusion
Reported as:
Number · percentage of participants
Progression-free Survival Rate at Four Months (PFS4)
percentage of participantsA - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)
Progression-free Survival Rate at Four Months (PFS4)27.3 (10.7 to 50.2)15.8 (3.4 to 39.6)26.1 (10.2 to 48.4)
Statistical analysis
  • A - Docetaxel · The exact binomial estimator: 29.2 · 95% CI 13.2 to 48.4
  • B - Lurbinectedin (PM01183) · The exact binomial estimator: 19.0 · 95% CI 5.7 to 37.9
  • C - Gemcitabine + Lurbinectedin (PM01183) · The exact binomial estimator: 28.0 · 95% CI 12.6 to 46.7
SecondaryProgression-free Survival

PFS, progression-free survival Progression-free survival (PFS), defined as the time from the date of randomization to the date of PD, death (of any cause), or last tumor evaluation. Progession disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Time frame:
Time from the date of randomization to the date of PD, death (of any cause), or last tumor evaluation, whichever came first, assessed up to 3 years
Reported as:
Median · months
Progression-free Survival
monthsA - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)
Progression-free Survival3.1 (1.8 to 4)1.9 (1.5 to 3)3.3 (1.9 to 5.7)
Statistical analysis
  • A - Docetaxel vs B - Lurbinectedin (PM01183) vs C - Gemcitabine + Lurbinectedin (PM01183) · Log Rank · p = = 0.3873
SecondaryProgression-free Survival Rate at Six Months (PFS6)

The rate estimate of the percentage of patients who are alive and progression-free at 24 weeks (\~6 months) after randomization. Progession disease was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression.

Time frame:
At month six after patient inclusion
Reported as:
Number · percentage of participants
Progression-free Survival Rate at Six Months (PFS6)
percentage of participantsA - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)
Progression-free Survival Rate at Six Months (PFS6)18.2 (2.1 to 34.3)16.7 (0 to 33.9)17.5 (0 to 35.2)
SecondaryOverall Response Rate

Overall response rate (ORR) was defined as the percentage of patients with a response, either CR or PR, according to RECIST v.1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Time from the date of randomization until 30±7 days after the last treatment infusion, assessed up to 3 years
Reported as:
Number · percentage of participants
Overall Response Rate
percentage of participantsA - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)
Overall Response Rate9.1 (1.1 to 29.2)0 (0 to 17.6)17.4 (5.0 to 38.8)
SecondaryObjective Response Per RECIST v.1.1

RECIST, Response Evaluation Criteria In Solid Tumors Complete Response (CR) Disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to \<10mm Partial Response (PR) At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum diameters Progressive Disease (PD) At least a 20% increase in the sum of diameters of target lesions taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. Appearance of new lesions was considered PD Stable Disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum diameters while on study Treatment failure (TF) Symptomatic deterioration/death due to progression or treatment discontinuation due to treatment-related toxicity occurred before any appropriate tumor assessments had been performed

Time frame:
Time from the date of randomization until 30±7 days after the last treatment infusion, assessed up to 3 years
Reported as:
Count of participants · Participants
Objective Response Per RECIST v.1.1
ParticipantsA - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)
PR204
SD10711
PD886
TF242
SecondaryDuration of Response

Duration of response (DR) was defined as the time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
The time from the date when the response criteria (PR or CR, whichever was reached first) were fulfilled, to the first date when PD, recurrence or death was documented, up to 3 years
Reported as:
Median · months
Duration of Response
monthsA - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)
Duration of Response1.2 (0.8 to 1.6)—6.1 (2.0 to NA)
Statistical analysis
  • A - Docetaxel vs C - Gemcitabine + Lurbinectedin (PM01183) · Log Rank · p = = 0.0177
SecondaryOverall Survival (OS)

Overall survival (OS) will be defined as time from the date of first infusion to the date of death or last contact

Time frame:
From the date of first infusion to the date of death or last contact, up to 12 months after last patient inclusion
Reported as:
Median · months
Overall Survival (OS)
monthsA - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)
Overall Survival (OS)9.4 (3.1 to NA)5.5 (3.0 to 8.0)7.2 (4.5 to 10.6)
Statistical analysis
  • A - Docetaxel vs B - Lurbinectedin (PM01183) vs C - Gemcitabine + Lurbinectedin (PM01183) · Log Rank · p = 0.3526
SecondaryInformation on Quality of Life (QoL)

The mean QoL scores self-reported by patients using the Lung Cancer Symptom Scale (LCSS) at baseline and after the start of the therapy in visits 3 or 6 (+/- 1 visit) and visit 9 for those patients in maintenance therapy. Higher LCSS scores indicate more severe problems and the scale range is (0-100) Total score was calculated as the mean of the total scores of all nine patient ítems (Appetite, Fatigue, Cough, Dyspnea, Hemoptysis, Pain, Lung cancer symptoms, Normal activities, Global QoL)

Time frame:
Baseline, Cycle 3 (~9 weeks), Cycle 6 (~18 weeks) and Cycle 9 (~27 weeks)
Reported as:
Mean · units on a scale
Information on Quality of Life (QoL)
units on a scaleA - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)
Baseline27.2 (18.4 to 36.1)36.4 (25.0 to 47.7)38.1 (27.7 to 48.5)
Cycle 329.5 (14.5 to 44.5)32.2 (19.5 to 44.9)36.4 (25.4 to 47.5)
Cycle 624.3 (17.4 to 31.1)55.4 (NA to NA)35.4 (-11.7 to 82.5)
Cycle 9—38.1 (-74.8 to 151.1)—
Statistical analysis
  • A - Docetaxel · Wilcoxon signed ranks test repeat analys · p = 0.9026
  • B - Lurbinectedin (PM01183) · Wilcoxon signed ranks test repeat analys · p = 0.9862
  • C - Gemcitabine + Lurbinectedin (PM01183) · Wilcoxon signed ranks test repeat analys · p = 0.8057

Adverse events

Collected over Participants were assessed through study completion, approximately 3 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
A - Docetaxel14/22 (63.6%)12/22 (54.5%)21/22 (95.5%)
B - Lurbinectedin (PM01183)17/21 (81%)9/21 (42.9%)20/21 (95.2%)
C - Gemcitabine + Lurbinectedin (PM01183)21/25 (84%)18/25 (72%)25/25 (100%)
Most frequent serious events
Showing 10 of 47
Most frequent serious events
EventA - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)
PneumoniaInfections and infestations3/220/214/25
Febrile neutropeniaBlood and lymphatic system disorders2/223/211/25
NeutropeniaBlood and lymphatic system disorders1/221/213/25
ThrombocytopeniaBlood and lymphatic system disorders0/221/213/25
Platelet count decreasedInvestigations0/222/211/25
Septic shockInfections and infestations2/220/210/25
Asthenia/FatigueGeneral disorders0/220/212/25
Cardiac failureCardiac disorders0/220/212/25
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/220/212/25
ShockVascular disorders0/221/210/25
Most frequent other events
Showing 10 of 45
Most frequent other events
EventA - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)
Asthenia/FatigueGeneral disorders16/2216/2117/25
AnaemiaBlood and lymphatic system disorders3/227/2115/25
NeutropeniaBlood and lymphatic system disorders4/223/2113/25
NauseaGastrointestinal disorders2/226/2113/25
Decreased appetiteMetabolism and nutrition disorders2/2210/218/25
VomitingGastrointestinal disorders2/228/216/25
CoughRespiratory, thoracic and mediastinal disorders8/225/214/25
DyspnoeaRespiratory, thoracic and mediastinal disorders8/225/217/25
PyrexiaGeneral disorders7/225/217/25
Abdominal painGastrointestinal disorders0/226/213/25

Baseline characteristics

69 patients were enrolled between 11/09/2013 and 2/10/2015 at 13 centers. 68 patients were treated: 22 in Arm A, 21 in Arm B, and 25 in Arm C. The first dose of the first cycle was administered on 17/09/2013 and the last dose of the last cycle was administered on 3/11/2016. The last patient, last follow-up was on 24/11/2016

Age, Categorical
Age, Categorical(Participants)A - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)Total
<=18 years0000
Between 18 and 65 years15101338
>=65 years7121231
Age, Continuous
Age, Continuous(years)A - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)Total
Median61.5 (49 to 72)65 (46 to 74)64 (41 to 75)63 (41 to 75)
Sex: Female, Male
Sex: Female, Male(Participants)A - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)Total
Female55919
Male17171650
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)A - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)Total
Race — Caucasian21222568
Race — Unknown1001
Region of Enrollment
Region of Enrollment(Participants)A - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)Total
United States2002
Italy8111332
Belgium0303
Spain1281232
ECOG PS
ECOG PS(Participants)A - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)Total
PS 06111027
PS 116111542
Histology type
Histology type(Participants)A - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)Total
Non-squamous-cell17181954
Squamous-cell44614
Not specified1001
Histology grade
Histology grade(Participants)A - DocetaxelB - Lurbinectedin (PM01183)C - Gemcitabine + Lurbinectedin (PM01183)Total
Well differentiated0101
Moderately differentiated2518
Poorly differentiated73919
Unknown13131541

15 further baseline measures are reported on the registry.

08

Study locations

1 site
  • New York, New York, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2013 to primary completion in Nov 2016, 38 months.

Results were first posted in Sep 2019, 2 years 10 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 38 months is close to that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2013
First posted
Sep 26, 2013
StartActual
Sep 11, 2013
Primary completionActual
Nov 2016
CompletionActual
Nov 2016
Results first posted
Sep 24, 2019
Last update
Sep 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01951157
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
Sep 26, 2013
Start date
Sep 11, 2013
Primary completion
Nov 2016
Completion
Nov 2016
Results posted
Sep 24, 2019
Last update
Sep 24, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PM 01183

Start the discussion